相似文献
1
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
Blood Adv. 2020 Sep 22;4(18):4508-4511. doi: 10.1182/bloodadvances.2020002454.
2
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
Br J Haematol. 2020 Oct;191(1):e22-e25. doi: 10.1111/bjh.16948. Epub 2020 Jul 17.
3
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Dec;62(12):3051-3053. doi: 10.1080/10428194.2021.1964023. Epub 2021 Aug 25.
4
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Intern Med. 2021 Oct 15;60(20):3305-3308. doi: 10.2169/internalmedicine.6979-20. Epub 2021 Apr 26.
5
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
Oncologist. 2020 Nov;25(11):974-980. doi: 10.1634/theoncologist.2020-0388. Epub 2020 Sep 20.
6
Ibrutinib Regimens in Older Patients with Untreated CLL.
N Engl J Med. 2019 Apr 25;380(17):1679. doi: 10.1056/NEJMc1901284.
7
Ibrutinib Regimens in Older Patients with Untreated CLL.
N Engl J Med. 2019 Apr 25;380(17):1679. doi: 10.1056/NEJMc1901284.
8
Ibrutinib Regimens in Older Patients with Untreated CLL.
N Engl J Med. 2019 Apr 25;380(17):1679-1681. doi: 10.1056/NEJMc1901284.
9
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
10
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.
Clin Cancer Res. 2021 Aug 15;27(16):4465-4467. doi: 10.1158/1078-0432.CCR-21-1589. Epub 2021 Jun 9.
引用本文的文献
1
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.
Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.
2
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome.
Cell Death Dis. 2024 May 9;15(5):323. doi: 10.1038/s41419-024-06707-5.
3
Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?
Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.
4
[Classification of indolent B-cell lymphomas : Novelties and open questions].
Pathologie (Heidelb). 2023 May;44(3):154-165. doi: 10.1007/s00292-023-01186-5. Epub 2023 Apr 24.
5
Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.
Am J Clin Pathol. 2023 Jun 1;159(6):554-571. doi: 10.1093/ajcp/aqad027.
6
Chronic lymphocytic leukemia treatment algorithm 2022.
Blood Cancer J. 2022 Nov 29;12(11):161. doi: 10.1038/s41408-022-00756-9.
7
An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.
J Adv Pract Oncol. 2022 Jul;13(5):535-538. doi: 10.6004/jadpro.2022.13.5.7. Epub 2022 Jul 27.
8
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
9
Biology and Treatment of Richter Transformation.
Front Oncol. 2022 Mar 22;12:829983. doi: 10.3389/fonc.2022.829983. eCollection 2022.
10
Life-Threatening Fungal Infection in Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Brief Review of Literature.
Cureus. 2021 Jun 25;13(6):e15924. doi: 10.7759/cureus.15924. eCollection 2021 Jun.
本文引用的文献
1
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.
2
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
3
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.
4
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Blood. 2019 May 30;133(22):2452-2455. doi: 10.1182/blood.2019896688. Epub 2019 Mar 27.
5
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.
6
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
7
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.
8
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.
9
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.
10
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.
Zotero 插件